Quick Answer
Sagimet Biosciences Inc. reported Operating Income Loss of -$56.89 million for the year ending 2025.
- Sagimet Biosciences Inc. showed a decrease of -4.5% in Operating Income Loss from 2024 to 2025.
- This data is from Sagimet Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: -$7.24 million | Q3 2022: -$7.69 million | Q1 2023: -$6.77 million | Q2 2023: -$7.06 million | Q3 2023: -$7.45 million | Q1 2024: -$8.77 million | Q2 2024: -$10.59 million | Q3 2024: -$16.90 million | Q1 2025: -$19.87 million | Q2 2025: -$11.93 million | Q3 2025: -$14.33 million.
- Over the full 4 years of available data (2022 to 2025), Sagimet Biosciences Inc.'s Operating Income Loss has declined by 83.2%.
- Historical annual values: Fiscal year 2025: -$56.89 million | Fiscal year 2024: -$54.45 million | Fiscal year 2023: -$30.74 million | Fiscal year 2022: -$31.06 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: